Bespak has signed a key new development agreement with Innovata Biomed, the respiratory division of ML Laboratories, which supplies inhaled drug delivery to the pharmaceutical industry
Bespak will develop Innovata Biomed's novel C200 multi-dose dry powder inhaler device for the delivery of combination drug therapies for diseases such as asthma.
Bespak will also supply IB with clinical trial quantities of devices.
In a separate announcement, ML Laboratories disclosed that IB has entered into an exclusive multi-million pound licence agreement with an undisclosed major global pharmaceutical group to market and distribute the new C200 inhaler in Europe.
Commenting on this agreement, Mark Throdahl, Bespak's chief executive, said: "We are delighted that IB has selected Bespak as its development partner.
"This agreement further highlights Bespak's strength and expertise in the field of respiratory drug delivery devices.
"We look forward to progressing this collaboration."
